SAB Biotherapeutics, Inc. (SABSW) Insider Ownership

Historic Insider Ownership Trends

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.
Holder Position Shares (Direct) Shares (Indirect) Report Date
Eddie Joe Sullivan Chief Executive Officer 5,232,304 0 08 Dec, 2023
Edward D. Hamilton - 5,092 5,049,351 26 Oct, 2021
Christine E Hamilton - 4,993,090 0 14 Sep, 2022
Andrew Moin - 0 4,584,571 28 Nov, 2023
Christine E Hamilton - 0 3,111,334 09 Dec, 2022
Helen K. Ellias - 0 2,857,142 28 Nov, 2023
Capital (Master), L.P. Sessa - 2,198,457 0 01 Oct, 2025
Andrew Moin - 0 2,198,457 01 Oct, 2025
Samuel J Reich Executive Chairman 0 547,698 23 May, 2022
Jeffrey G Spragens - 394,989 0 09 Dec, 2022
Samuel J Reich Executive Chairman 219,001 0 30 Nov, 2023
David Charles Link - 57,313 0 09 Dec, 2022
Alexandra Kropotova Chief Medical Officer 43,296 0 25 Mar, 2026
Frederick Finnegan Chief Business Officer 38,596 0 26 Oct, 2021
Christine E Hamilton - 0 25,000 26 Oct, 2021
David Charles Link - 0 12,097 26 Oct, 2021
Thomas Charles Luke Chief Medical Officer 5,428 0 26 Oct, 2021
Michael King Chief Financial Officer 5,000 0 30 Nov, 2023
Russell P Beyer Chief Financial Officer 2,475 15 16 Nov, 2021
Ilan Katz - 1,500 0 15 Oct, 2021
Samuel J Reich Ceo And Cfo 1,000 0 15 Oct, 2021

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.
Download Data
Transaction Date Insider Name Security Class Transaction Type Shares Traded Price Shares Remaining Ownership Code
24 Mar, 2026 Alexandra Kropotova Common Stock D 988 - 43,296 D F
03 Feb, 2026 Christoph Lawrence Bausch Stock option (right to buy) A 1,800,000 $0.00 1,800,000 D A
03 Feb, 2026 Samuel J Reich Stock option (right to buy) A 4,800,000 $0.00 4,800,000 D A
03 Feb, 2026 Lucy To Stock option (right to buy) A 2,400,000 $0.00 2,400,000 D A
03 Feb, 2026 Eddie Joe Sullivan Stock option (right to buy) A 3,000,000 $0.00 3,000,000 D A
03 Feb, 2026 Alexandra Kropotova Stock option (right to buy) A 2,400,000 $0.00 2,400,000 D A
05 Jan, 2026 Rita Jain Stock Option (right to buy) A 240,000 $0.00 240,000 D A
05 Jan, 2026 David Zaccardelli Stock Option (right to buy) A 240,000 $0.00 240,000 D A
16 Dec, 2025 David Link Stock Option (right to buy) A 150,000 $0.00 150,000 D A
16 Dec, 2025 Helen K. Ellias Stock Option (right to buy) A 150,000 $0.00 150,000 D A
16 Dec, 2025 William James Polvino Stock Option (right to buy) A 150,000 $0.00 150,000 D A
16 Dec, 2025 Jay S Skyler Stock Option (right to buy) A 150,000 $0.00 150,000 D A
16 Dec, 2025 Scott Giberson Stock Option (right to buy) A 150,000 $0.00 150,000 D A
16 Dec, 2025 Erick Lucera Stock option (right to buy) A 150,000 $0.00 150,000 D A
11 Dec, 2025 Alexandra Kropotova Common Stock D 988 - 44,284 D F
29 Sep, 2025 Andrew Moin Common Stock A 1,740,000 $1.75 2,198,457 I M
29 Sep, 2025 Capital (Master), L.P. Sessa Common Stock A 1,740,000 $1.75 2,198,457 D M
29 Sep, 2025 Capital (Master), L.P. Sessa Series B Convertible Preferred Stock D 17,400 - 211,100 D M
29 Sep, 2025 Andrew Moin Series B Convertible Preferred Stock D 17,400 - 211,100 I M
19 Sep, 2025 Alexandra Kropotova Common Stock D 1,977 - 45,272 D F